Inter- and intraindividual variability of long-acting injectable cabotegravir/rilpivirine trough concentrations after 1 year of continuous use
Journal of Antimicrobial Chemotherapy · 04.08.2026 · 81 (9)
DOI: 10.1093/jac/dkag282 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 11.08.2026. Verfasst von Shawnalyn W Sunagawa und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA. Hauptthemen laut MEDLINE: Rilpivirine, Anti-HIV Agents, HIV Infections, Pyridones. Die Arbeit nennt 28 Literaturangaben. Gefördert von: University of Nebraska Medical Center Clinical Research Support Fund, Nebraska Tobacco Settlement Biomedical Research Development Fund.
Abstract (Originalsprache)
Objectives
Long-acting injectable (LAI) cabotegravir/rilpivirine demonstrates substantial inter- and intraindividual variability in trough concentrations during the first year of use. We aimed to characterize trough concentration variability of cabotegravir and rilpivirine after >12 months of continuous use.
Methods
We conducted a prospective pharmacokinetic study in virologically suppressed people with HIV receiving bimonthly LAI cabotegravir/rilpivirine 600 mg/900 mg. Plasma trough samples were collected prior to three consecutive doses over 6 months for drug quantitation. Primary outcomes were inter- and intraindividual variability defined as coefficient of variation (CV) and intraclass correlation coefficient (ICC). Secondary outcomes included concentrations below the proposed 4x-protein-adjusted 90% inhibitory concentration (PA-IC90) for cabotegravir (4x-PA-IC90 = 664 ng/mL) and rilpivirine (4x-PA-IC90 = 48 ng/mL).
Results
Among 50 participants, 150 samples were collected. Participants were primarily male (80%) with a median age of 45 years and a body mass index of 28 kg/m2. Median interindividual CVs were high for both cabotegravir [58%, interquartile range (IQR): 15, 59] and rilpivirine (52%, IQR: 18, 59). Median intraindividual CVs were moderate for both cabotegravir (24%, IQR: 15, 39) and rilpivirine (23%, IQR: 15, 39), with ICCs indicating good intraindividual agreement for cabotegravir (0.82) and moderate intraindividual agreement for rilpivirine (0.72). Twelve (8%) cabotegravir concentrations in 8 participants and 24 (16%) rilpivirine concentrations in 16 participants were below 4x-PA-IC90; however, all participants maintained virologic suppression throughout the study period.
Conclusions
After one year of continuous use, inter- and intraindividual variability persists for cabotegravir and rilpivirine, indicating that clinical decisions should not be based on only one trough concentration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy Practice and Science, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
- Antiviral Pharmacology Laboratory, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
- Division of Infectious Diseases, College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
- Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA.
ORCID-Profile: Shawnalyn W Sunagawa, Sara H Bares, Elizabeth Lyden, Courtney V Fletcher, Kimberly K Scarsi
Förderung
- University of Nebraska Medical Center Clinical Research Support Fund
- Nebraska Tobacco Settlement Biomedical Research Development Fund
Zitieren
APA
Sunagawa, S. W., Havens, J. P., Bares, S. H., Kubat, M., O'Neill, J., Lyden, E., Mykris, T., Winchester, L. C., Weinhold, J., Avedissian, S. N., Podany, A. T., Fletcher, C. V., & Scarsi, K. K. (2026). Inter- and intraindividual variability of long-acting injectable cabotegravir/rilpivirine trough concentrations after 1 year of continuous use. Journal of Antimicrobial Chemotherapy, 81(9). https://doi.org/10.1093/jac/dkag282
Vancouver
Sunagawa SW, Havens JP, Bares SH, Kubat M, O'Neill J, Lyden E, et al. Inter- and intraindividual variability of long-acting injectable cabotegravir/rilpivirine trough concentrations after 1 year of continuous use. Journal of Antimicrobial Chemotherapy. 2026;81(9). doi:10.1093/jac/dkag282
BibTeX
@article{Sunagawa2026,
author = {Sunagawa, Shawnalyn W and Havens, Joshua P and Bares, Sara H and Kubat, Maureen and O'Neill, Jennifer and Lyden, Elizabeth and Mykris, Timothy and Winchester, Lee C and Weinhold, Jonathan and Avedissian, Sean N and Podany, Anthony T and Fletcher, Courtney V and Scarsi, Kimberly K},
title = {Inter- and intraindividual variability of long-acting injectable cabotegravir/rilpivirine trough concentrations after 1 year of continuous use},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {9},
doi = {10.1093/jac/dkag282}
}
EUVIMED